-
公开(公告)号：EP0596032B2
公开(公告)日：2004-04-07
申请号：EP92917479.5
申请日：1992-07-24
IPC分类号： A61K39/00
CPC分类号： A61K39/39 , A61K9/1075 , A61K39/0011 , A61K39/015 , A61K39/12 , A61K2039/525 , A61K2039/55566 , C12N2740/16134 , Y02A50/396 , Y02A50/412
摘要： A compsn. is new, and comprises an antigen (I), except an albumin, mixed with an antigen formulation (II) consisting of: a stabilising detergent; a micelle-forming agent; and a biodegradable and biocompatible oil. (II) is a stable oil-in-water emulsion. Also new is a method for inducing a cytotoxic T-lymphocyte response in a human or animal comprising administering (I) and (II), (II) lacking an immunostimulating peptide component. (I) may be antigenic portions of HIV gp120, malaria antigens, CS protein and Sprorozoite surface protein, influenza antigens, carcinoma P21, etc. (I) also may not include a B-cell lymphoma anitgen.
-
2.发明公开COMBINATION THERAPY FOR TREATMENT OF AUTOIMMUNE DISEASES USING B CELL DEPLETING/IMMUNOREGULATORY ANTIBODY COMBINATION 审中-公开联合疗法用于自身免疫性疾病的治疗中使用的组合B-CELL除去剂/免疫调节ANTIBODIES
公开(公告)号：EP1328320A2
公开(公告)日：2003-07-23
申请号：EP01971112.6
申请日：2001-09-18
发明人： HANNA, Nabil
IPC分类号： A61P37/00 , A61K39/395 , A61K47/48 , A61K51/10
摘要： The present invention concerns treatment of autoimmune diseases with the combination of an immunoregulatory antibody, e.g. and anti-B7.1 or anti-B7.2 or anti-CD40L antibody and at least one B cell antibody, such as CD19, CD20, CD22, CD23, or CD37, wherein such antibodies may be administered separately, or in combination, and in either, over prolonged periods of time.
-
3.发明公开TREATMENT OF B CELL MALIGNANCIES USING ANTI-CD40L ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES AND/OR CHEMOTHERAPEUTICS AND RADIOTHERAPY 审中-公开FOR使用针对CD40L B细胞恶性疾病的处理方法靶向抗体针对CD20用靶向抗体和/或其化疗药物放射治疗
公开(公告)号：EP1229935A1
公开(公告)日：2002-08-14
申请号：EP00986212.9
申请日：2000-11-06
发明人： HANNA, Nabil , HARIHARAN, Kandasamy
IPC分类号： A61K39/395 , A61K51/10 , A61P35/02
CPC分类号： C07K16/2887 , A61K39/39533 , A61K51/1027 , A61K2039/505 , A61K2039/507 , C07K16/2827 , C07K16/2851 , C07K16/2875 , C07K2317/24 , A61K39/395 , A61K33/24 , A61K31/00 , A61K2300/00
摘要： The invention discloses compositions, combination therapies and methods of treating B-cell lymphomas and leukemias, as well as other CD40+ malignancies. The primary active agent of the composition is an anti-CD40L antibody or other CD40L antagonist that inhibits CD40-CD40L interaction. Compositions may additionally contain or utilize any one or more of the following in combination for the treatment of said disease: anti-CD20 antibodies, chemotherapeutic agents, chemotherapy cocktails, and radiotherapy.
-
4.发明公开TREATMENT OF AUTOIMMUNE DISEASES WITH ANTAGONISTS WHICH BIND TO B CELL SURFACE MARKERS 无效自身免疫性疾病的WITH拮抗剂治疗B细胞BIND下述表面标志物
公开(公告)号：EP1176981A1
公开(公告)日：2002-02-06
申请号：EP00928991.9
申请日：2000-05-04
IPC分类号： A61K39/395 , A61P37/00 , A61K47/48
CPC分类号： A61K39/3955 , A61K31/365 , A61K31/56 , A61K45/06 , A61K47/6849 , A61K51/1027 , A61K2039/505 , A61K2039/54 , C07K16/2803 , C07K16/2887 , C07K2317/24 , Y10S424/801 , Y10S424/81
摘要： The present invention concerns treatment of autoimmune diseases with antagonists which bind to B cell surface markers, such as CD19 or CD20.
-
公开(公告)号：EP1157042A1
公开(公告)日：2001-11-28
申请号：EP00913253.1
申请日：2000-01-28
发明人： BRASLAWSKY, Gary, Ronald , HANNA, Nabil , HARIHARAN, Kandasamy , LABARRE, Michael, J. , HUYNH, Tri, B.
CPC分类号： C07K16/2887 , A61K47/6835 , A61K2039/505 , C07K16/2851 , C07K16/468 , C07K2317/31 , C07K2317/734
摘要： The present invention relates to a novel process for the preparation of biologically active antibody dimers in a pharmaceutically acceptable composition. The dimers can be composed of two antibody molecules having the same antigen binding specificity and linked through a reducible, disulfide, or a non-reducible thioether, bond (homodimer). Alternatively, the dimers can be composed of two different antibody molecules having binding specificity for two distinct antigens (heterodimer). These dimers are useful for inducing hyper-cross-linking of membrane antigens. The present invention further relates to the use of biologically active antibody dimers for the preferential killing or inhibition of selected cell populations in the treatment of diseases such as cancer and autoimmune disorders.
-
6.发明公开SYNERGISTIC COMPOSITION AND METHODS FOR TREATING NEOPLASTIC OR CANCEROUS GROWTHS AND FOR RESTORING OR BOOSTING HEMATOPOIESIS 审中-公开协同组合物和方法用于治疗癌症或肿瘤样生长及恢复或起搏造血
公开(公告)号：EP1015031A1
公开(公告)日：2000-07-05
申请号：EP98949313.5
申请日：1998-09-17
CPC分类号： A61K39/00 , A61K9/1075 , A61K39/0011 , A61K39/12 , A61K39/39 , A61K39/39558 , A61K2039/505 , A61K2039/55516 , A61K2039/55522 , A61K2039/55555 , A61K2039/55566 , A61K2039/57 , A61K2039/585 , C07K16/22 , C07K2317/76 , C12N2710/20034 , Y02A50/412 , Y02A50/464 , A61K2300/00
摘要： The present invention provides a synergistic composition and methods for treating neoplastic or cancerous growths as well as for treating such patients in order to restore or boost hematopoiesis. The present invention comprises administration of the combination of a cytotoxic T-lymphocyte inducing composition and at least one agent which is capable of neutralizing or down regulating the activity of tumor secreted immunosuppressive factors, separately or in combination.
-
7.发明公开IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGENS 失效BETWEEN良心和人抗体共刺激抗原B7.1（CD80）和B7.2的结合相互作用的鉴定（CD28）
公开(公告)号：EP1007090A1
公开(公告)日：2000-06-14
申请号：EP97913955.7
申请日：1997-10-29
IPC分类号： A61K39/395 , C07K16/18 , C07K16/28
CPC分类号： C07K16/2827 , A61K38/00 , A61K2039/505 , C07K2317/21 , C07K2317/55 , C07K2317/76
摘要： The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.
-
8.发明公开
公开(公告)号：EP0854730A1
公开(公告)日：1998-07-29
申请号：EP96919365.0
申请日：1996-06-06
发明人： BRAMS, Peter , CHAMAT, Soulaima, Salim , PAN, Li-Zhen , WALSH, Edward, E. , HEARD, Cheryl, Janne , NEWMAN, Roland, Anthony
CPC分类号： C07K14/005 , A61K38/00 , A61K2039/505 , C07K16/00 , C07K16/1027 , C07K2317/21 , C07K2317/92 , C12N2760/18522 , C12N2799/028
摘要： A highly efficient method for generating human antibodies in particular which are specific to be RSV fusion protein which combines in vitro priming of human spleen cells and antigen boosting in SCID mice is taught. This method provides for very high human antibody titers which are predominantly of the IgG isotype which contain antibodies of high specificity and affinity to desired antigens. This method is well suited for generating human monoclonal antibodies for therapeutic and diagnostic applications as well as for rescue for human cells for generation of combinational human antibody gene libraries. Two human monoclonal antibodies, RF-1 and RF-2 which each possess an affinity for RSV-F protein « 2x10-9 Molar are taught as well as their corresponding amino acid and DNA sequences. These antibodies are to be used therapeutically and prophylactically for treating or preventing RSV infection, as well as for diagnosis of RSV in analytes.
-
9.发明授权THERAPEUTIC APPLICATION OF CHIMERIC AND RADIOLABELED ANTIBODIES TO HUMAN B LYMPHOCYTE RESTRICTED DIFFERENTIATION ANTIGEN FOR TREATMENT OF B CELL LYMPHOMA 失效人B淋巴细胞分化抗原的嵌合和标记抗体的治疗用途有限B细胞于治疗LYMPHOMA-
公开(公告)号：EP0669836B1
公开(公告)日：1996-07-03
申请号：EP94901444.3
申请日：1993-11-12
发明人： ANDERSON, Darrell, R. , RASTETTER, William, H. , HANNA, Nabil , LEONARD, John, E. , NEWMAN, Roland, A. , REFF, Mitchell, E.
IPC分类号： A61K39/395 , A61K51/00 , C12N15/02 , C12P21/08
CPC分类号： C07K16/2887 , A61K38/00 , A61K47/6849 , A61K51/1027 , A61K51/1093 , A61K2039/505 , C07K2317/24 , C07K2317/56 , C07K2317/732 , C07K2319/00 , C12N2799/028 , Y10S424/80 , Y10S424/801 , Y10S530/808 , Y10S530/809 , Y10S530/867
摘要： Disclosed herein are therapeutic treatment protocols designed for the treatment of B cell lymphoma. These protocols are based upon therapeutic strategies which include the use of administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies, and cooperative strategies comprising the use of chimeric anti-CD20 antibodies and radiolabeled anti-CD20 antibodies.
摘要翻译： 在治疗性治疗方案被设计用于B细胞淋巴瘤的公开的治疗。 这些协议是基于治疗策略，包括使用免疫活性鼠/人嵌合抗CD20抗体，放射性标记的抗CD20抗体，合作策略，包括使用嵌合抗CD20抗体和放射性标记的抗CD20抗体的管理。
-
10.发明公开Methods for selecting antibody reagents; anti-idiotype antibodies; and aids vaccine formulations 失效Verfahren zur AuswahlAntikörperreagenzes; 抗独特型Antikörper; 和Aidsimpfstoffabfassungen。
公开(公告)号：EP0503916A1
公开(公告)日：1992-09-16
申请号：EP92302064.8
申请日：1992-03-11
发明人： Chang-Yuil Kang
IPC分类号： G01N33/569 , G01N33/68 , A61K39/21 , C12P21/08
CPC分类号： G01N33/686 , A61K39/00 , C07K16/1063 , C07K16/4225 , G01N33/56988
摘要： A novel method is disclosed for selecting antibody reagents for vaccine formulations that are capable of inducing group-neutralizing anti-HIV antibody responses in humans. Also disclosed are anti-idiotype antibodies and hybridoma cell lines capable of producing such antibodies. Further, anti-idiotype antibody-based vaccines and formulations thereof are disclosed. The methods, antibodies, hybridomas and vaccine formulations of the present invention may be useful in the treatment and prevention of HIV infection.
摘要翻译： 公开了一种新型方法，用于选择能诱导人群中中和的抗HIV抗体应答的疫苗制剂的抗体试剂。 还公开了能够产生这种抗体的抗独特型抗体和杂交瘤细胞系。 此外，公开了抗独特型抗体基疫苗及其制剂。 本发明的方法，抗体，杂交瘤和疫苗制剂可用于治疗和预防HIV感染。
-
-
-
-
-
-
-
-
-
搜索结果
57 条记录 (耗时 0.033 秒)
